Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities.

Thaer Idrees, Iris Castro-Revoredo, Sriya Kantipudi, Guillermo Umpierrez
Author Information
  1. Thaer Idrees: Division of Endocrinology, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Jr Dr, Atlanta, GA, 30309, USA. thaer.idrees@emory.edu.
  2. Iris Castro-Revoredo: Division of Endocrinology, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Jr Dr, Atlanta, GA, 30309, USA.
  3. Sriya Kantipudi: Division of Endocrinology, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Jr Dr, Atlanta, GA, 30309, USA.
  4. Guillermo Umpierrez: Division of Endocrinology, Department of Medicine, Emory University School of Medicine, 69 Jesse Hill Jr Dr, Atlanta, GA, 30309, USA.

Abstract

PURPOSE OF REVIEW: This narrative review aims to explore the literature on advancements in diabetes management within long-term care facilities (LTCFs). Managing chronic diseases like diabetes in LTCFs is particularly challenging due to the dynamic nature of these environments and the significant changes they have undergone over the past decade. Various factors, including rising care costs and government regulations, influence the quality-of-care residents receive in these settings.
RECENT FINDINGS: Many diabetes medications have not been extensively studied in LTCFs, and high-risk medications such as sulfonylureas and sliding scale insulin are still in use, potentially increasing the risk of morbidity and mortality among residents. Additionally, the adoption of diabetes technologies, such as continuous glucose monitors (CGMs) and insulin pumps, remains limited in LTCFs. Despite the high prevalence of diabetes, significant research gaps persist. Diabetes technologies have the potential to greatly improve diabetes management and outcomes for residents. However, more research is needed to evaluate their efficacy and safety in long-term care settings. Furthermore, there is a pressing need to address the gap in staff training on the use of these technologies. Closing these research gaps is essential for developing evidence-based guidelines and improving the quality of diabetes care in LTCFs.

Keywords

References

  1. National Academies of Sciences, E., and, Medicine. Evolution and landscape of nursing home care in the united States. National Academies; 2022.
  2. Long-Term care in the united States: A timeline. KFF, 2015.
  3. The National imperative to improve nursing home quality: honoring our commitment to residents, families, and staff. 2022: Washington (DC).
  4. CDC. Nursing Home Care. National Center for Health Sciences. 2024; Available from: https://www.cdc.gov/nchs/fastats/nursing-home-care.htm#print
  5. National Academies Press (US). C.o.t.Q.o.C.i.N.H., The National imperative to improve nursing home quality: honoring our commitment to residents, families, and staff. National library of medicine 2022. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services.
  6. Services CfMM. Projected. National health expenditure data 2024; Available from: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/projected
  7. Bundled Payments for Care Improvement (BPCI) Initiative: General Information. 2021; Available from: https://www.cms.gov/priorities/innovation/innovation-models/bundled-payments
  8. Geng F, Stevenson DG, Grabowski DC. Daily nursing home staffing levels highly variable, often below CMS expectations. Health Aff (Millwood). 2019;38(7):1095���100. [PMID: 31260368]
  9. Paulin E. Worker Shortages in Nursing Homes Hit Pandemic Peak as COVID-19 Deaths Continue, in AARP. 2021, Simon & Schuster.
  10. Ong KL, et al. Global, regional, and National burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203���34.
  11. Prevention C. f.D.C.a. National Diabetes Statistics Report website. 12/12/2024]; Available from: https://www.cdc.gov/diabetes/php/data-research/?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report/index.html
  12. Parker ED, et al. Economic costs of diabetes In the U.S. In 2022. Diabetes Care. 2023;47(1):26���43.
  13. Morley JE. An overview of diabetes mellitus in older persons. Clin Geriatr Med. 1999;15(2):211���24. [PMID: 10339629]
  14. Boyle JP, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U. S Diabetes Care. 2001;24(11):1936���40. [PMID: 11679460]
  15. Narayan KM, et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005���2050. Diabetes Care. 2006;29(9):2114���6. [PMID: 16936162]
  16. CDC. National Diabetes Statistics Report. 2024 May 15 2024 [cited 2024; Available from: https://www.cdc.gov/diabetes/php/data-research/index.html
  17. Yang K, et al. Global burden of type 1 diabetes in adults aged 65 years and older, 1990���2019: population based study. BMJ. 2024;385:e078432. [PMID: 38866425]
  18. Patterson C, et al. Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(2):161���75. [PMID: 24331235]
  19. Munshi MN, et al. Management of diabetes in Long-term care and skilled nursing facilities: A position statement of the American diabetes association. Diabetes Care. 2016;39(2):308���18. [PMID: 26798150]
  20. Newton CA, et al. Prevalence, quality of care, and complications in long term care residents with diabetes: a multicenter observational study. J Am Med Dir Assoc. 2013;14(11):842���6. [PMID: 24055534]
  21. Dybicz SB, et al. Prevalence of diabetes and the burden of comorbid conditions among elderly nursing home residents. Am J Geriatr Pharmacother. 2011;9(4):212���23. [PMID: 21659006]
  22. Hassan S, et al. Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward. Lancet Diabetes Endocrinol. 2023;11(7):509���24. [PMID: 37356445]
  23. Cheng YJ, et al. Prevalence of diabetes by race and ethnicity in the united States, 2011���2016. JAMA. 2019;322(24):2389���98. [PMID: 31860047]
  24. Elhussein A et al. Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the look AHEAD study. Lancet Reg Health Am, 2022. 6.
  25. Lee DC, Ta���Loria MMS, Christian Y, Koziatek A, Christopher MD, Shim J, Marcela JDMS, Andrew O, Vinson J, Joseph MA, Ravenell E, Stephen MDMS, Wall P. MD, MSc, MAEd. Age Disparities Among Patients With Type 2 Diabetes and Associated Rates of Hospital Use and Diabetic Complications. CDC 2019 August 1, 2019; Volume 16:[PREVENTING CHRONIC DISEASE].
  26. (CMS). C.f.M.M.S. Racial and Ethnic Disparities in Diabetes Prevalence, Self-Management, and Health Outcomes among Medicare Beneficiaries. Medicare Current Benefciary Survey (MCBS) 2017 [cited 2024 12/12]; Available from: https://www.cms.gov/About-CMS/Agency-Information/OMH/Downloads/March-2017-Data-Highlight.pdf
  27. Smith JM et al. Racial disparities in Post-Acute home health care referral and utilization among older adults with diabetes. Int J Environ Res Public Health, 2021. 18(6).
  28. Rivera-Hernandez M, et al. Quality of Post-Acute care in skilled nursing facilities that disproportionately serve black and Hispanic patients. J Gerontol Biol Sci Med Sci. 2019;74(5):689���97.
  29. Grabowski DC, McGuire TG. Black-White disparities in care in nursing homes. Atl Econ J. 2009;37(3):299���314. [PMID: 20160968]
  30. Racial Disparities in Nursing Home Care. 2024 March 12, 2024; Available from: https://www.nursinghomeabusecenter.com/blog/nursing-home-race-disparities/
  31. Neuwahl SJ, et al. Diabetes-Attributable nursing home costs for each U.S. State. Diabetes Care. 2018;41(7):1455���61. [PMID: 29760123]
  32. Aguayo GA, Fagherazzi G. Intricate relationships between frailty and diabetes: where do we go from here? Lancet Healthy Longev. 2020;1(3):e92���3. [PMID: 36094190]
  33. Ida S, et al. Relationship between frailty and mortality, hospitalization, and cardiovascular diseases in diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18(1):81. [PMID: 31215496]
  34. O���Caoimh R, et al. Frailty in an adult acute hospital population: predictors, prevalence, and outcomes. Int J Environ Res Public Health. 2024;21(3):273. [PMID: 38541274]
  35. Buckinx F, et al. Prevalence of frailty in nursing home residents according to various diagnostic tools. J Frailty Aging. 2017;6:122���8. [PMID: 28721427]
  36. Sinclair AJ, Rodriguez-Ma��as L. Diabetes and frailty: two converging conditions?? Can J Diabetes. 2016;40(1):77���83. [PMID: 26683240]
  37. Abd Ghafar MZA, et al. Frailty and diabetes in older adults: overview of current controversies and challenges in clinical practice. Front Clin Diabetes Healthc. 2022;3:895313. [PMID: 36992729]
  38. Meneilly GS, Elahi D. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care. 2005;28(6):1498���9. [PMID: 15920078]
  39. Sinclair AJ, Abdelhafiz AH. Unravelling the frailty syndrome in diabetes. Lancet Healthy Longev. 2021;2(11):e683���4. [PMID: 36098024]
  40. Chao CT, et al. Hypoglycemic episodes are associated with an increased risk of incident frailty among new onset diabetic patients. J Diabetes Complications. 2020;34(2):107492. [PMID: 31806427]
  41. Lee JS, et al. Transitions in frailty States among community-living older adults and their associated factors. J Am Med Dir Assoc. 2014;15(4):281���6. [PMID: 24534517]
  42. Crews RT, et al. A growing troubling triad: diabetes, aging, and falls. J Aging Res. 2013;2013:p342650.
  43. Schwartz AV, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31(3):391���6. [PMID: 18056893]
  44. Idrees T et al. Update on the management of diabetes in long-term care facilities. BMJ Open Diabetes Res Care, 2022. 10(4).
  45. Davidson HE et al. Clinical practice guideline for diabetes management in the Post-Acute and Long-Term care setting. J Am Med Dir Assoc, 2024. 25(11).
  46. Geller AI, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174(5):678���86. [PMID: 24615164]
  47. Stahn A, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014;37(2):516���20. [PMID: 24041680]
  48. Lee AK, et al. Severe hypoglycemia and risk of falls in type 2 diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2020;43(9):2060���5. [PMID: 32611607]
  49. Lega IC, Rochon PA. Diabetes treatment deintensification in nursing homes: when less is more. J Am Geriatr Soc. 2022;70(7):1946���9. [PMID: 35587266]
  50. Niznik JD, et al. Effect of deintensifying diabetes medications on negative events in older veteran nursing home residents. Diabetes Care. 2022;45(7):1558���67. [PMID: 35621712]
  51. Davidson HE, et al. Clinical practice guideline for diabetes management in the Post-Acute and Long-Term care setting. J Am Med Dir Assoc. 2024;25(11):105342. [PMID: 39401750]
  52. Pandya N, et al. Medication prescribing for type 2 diabetes in the US Long-Term care setting: observational study. J Am Med Dir Assoc. 2023;24(6):790���e7974. [PMID: 37094748]
  53. Schlender L, et al. Efficacy and safety of Metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2017;17(Suppl 1):227. [PMID: 29047344]
  54. Zoungas S, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410���8. [PMID: 20925543]
  55. Bennett WL, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602���13. [PMID: 21403054]
  56. Lv W, et al. Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem. 2020;20(1):37���56. [PMID: 31884929]
  57. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res. 1996;28(9):456���63. [PMID: 8911983]
  58. Lam K, et al. Sliding scale insulin use in a National cohort study of nursing home residents with type 2 diabetes. J Am Geriatr Soc. 2022;70(7):2008���18. [PMID: 35357692]
  59. Committee ADAPP. 13. Older adults: standards of care in Diabetes���2024. Diabetes Care. 2023;47(Supplement1):S244���57.
  60. Franchin A, et al. The gestio protocol experience: safety of a standardized order set for subcutaneous insulin regimen in elderly hospitalized patients. Aging Clin Exp Res. 2017;29(6):1087���93. [PMID: 28238154]
  61. Silverberg AB, Ligaray KP. Oral diabetic medications and the geriatric patient. Clin Geriatr Med. 2008;24(3):541���9. viii. [PMID: 18672188]
  62. Umpierrez GE, et al. A randomized controlled study comparing a DPP4 inhibitor (Linagliptin) and basal insulin (Glargine) in patients with type 2 diabetes in Long-term care and skilled nursing facilities: Linagliptin-LTC trial. J Am Med Dir Assoc. 2018;19(5):399���e4043. [PMID: 29289540]
  63. Jurgens CY, et al. Heart failure management in skilled nursing facilities: a scientific statement from the American heart association and the heart failure society of America. Circ Heart Fail. 2015;8(3):655���87. [PMID: 25855686]
  64. Wolverton D, Blair MM. Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Am J Health Syst Pharm. 2017;74(15):1143���51. [PMID: 28743778]
  65. Guja C, Guja L, Miulescu RD. Effect of type 2 diabetes medications on fracture risk. Ann Transl Med. 2019;7(20):580. [PMID: 31807561]
  66. Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (PROspective PioglitAzone clinical trial in macrovascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279���89. [PMID: 16214598]
  67. Dormuth CR, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395���402. [PMID: 19667303]
  68. Giugliano D, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract. 2020;162:108114. [PMID: 32165164]
  69. Tsapas A, et al. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract. 2021;177:108921. [PMID: 34144086]
  70. Karagiannis T, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737. [PMID: 33705820]
  71. Zavattaro M, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620���6. [PMID: 25572181]
  72. von Scholten BJ, et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications. 2015;29(5):670���4.
  73. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311���22. [PMID: 27295427]
  74. Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109���21. [PMID: 38785209]
  75. Yildirim Simsir I, Soyaltin UE, Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer���s disease. Diabetes Metab Syndr. 2018;12(3):469���75. [PMID: 29598932]
  76. Femminella GD, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer���s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019;20(1):191. [PMID: 30944040]
  77. Wilding JPH, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989���1002. [PMID: 33567185]
  78. McCrimmon RJ, et al. Effects of once-weekly semaglutide vs once-daily Canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473���85. [PMID: 31897524]
  79. Jiang BC, Villareal DT. Weight Loss-Induced reduction of bone mineral density in older adults with obesity. J Nutr Gerontol Geriatr. 2019;38(1):100���14. [PMID: 30794099]
  80. Daniilopoulou I et al. The impact of GLP1 agonists on bone metabolism: A systematic review. Med (Kaunas), 2022. 58(2).
  81. Zhong P, et al. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022;75(3):718���24. [PMID: 34981419]
  82. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205���16. [PMID: 35658024]
  83. Dent E, et al. Malnutrition in older adults. Lancet. 2023;401(10380):951���66. [PMID: 36716756]
  84. Idrees T, Umpierrez GE. Beyond pounds: what else could be lost? J Diabetes Complications. 2023;37(12):108649. [PMID: 37992414]
  85. Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31���9. [PMID: 30424892]
  86. Rhee JJ, et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020;22(Suppl 1):46���54. [PMID: 32267076]
  87. Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of Sodium-Glucose cotransporter 2 inhibitors: JACC State-of-the-Art review. J Am Coll Cardiol. 2020;75(4):435���47. [PMID: 32000956]
  88. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 2022. 400(10365): pp. 1788���801.
  89. Cahn A, et al. Efficacy and safety of Dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study. Diabetes Care. 2020;43(2):468���75. [PMID: 31843945]
  90. Monteiro P, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing. 2019;48(6):859���66. [PMID: 31579904]
  91. Smith PW, et al. SHEA/APIC guideline: infection prevention and control in the long-term care facility. Am J Infect Control. 2008;36(7):504���35. [PMID: 18786461]
  92. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434���8. [PMID: 30207042]
  93. Peters AL, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with Sodium-Glucose cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687���93. [PMID: 26078479]
  94. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295���311. [PMID: 30933547]
  95. Gorina Y, et al. Prevalence of incontinence among older Americans. Vital Health Stat. 2014;3(36):1���33.
  96. Committee ADAPP. 7. Diabetes technology: standards of care in Diabetes���2024. Diabetes Care. 2023;47(Supplement1):S126���44.
  97. Bao S, et al. Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin. Diabetes Technol Ther. 2022;24(5):299���306. [PMID: 34939824]
  98. Pratley RE, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial. JAMA. 2020;323(23):2397���406. [PMID: 32543682]
  99. Boureau AS, et al. Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: the HYPOAGE observational study. J Am Geriatr Soc. 2023;71(7):2107���19. [PMID: 36965179]
  100. Ruedy KJ, et al. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11(6):1138���46. [PMID: 28449590]
  101. Newton CA, et al. Prevalence, quality of care and complications in Long-Term care residents with diabetes: A multicenter observational study. JAMDA; 2013.
  102. Pasquel FJ, et al. A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities. BMJ Open Diabetes Res Care. 2015;3(1):e000104. [PMID: 26336609]
  103. Kalyani RR, Egan JM. Diabetes and altered glucose metabolism with aging. Endocrinol Metab Clin North Am. 2013;42(2):333���47. [PMID: 23702405]
  104. Thomson FJ, et al. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing. 1991;20(6):404���6. [PMID: 1776586]
  105. Shorr RI, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681���6. [PMID: 9250229]
  106. Lipska KJ, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116���24. [PMID: 24838229]
  107. Sinclair A, Dunning T, Rodriguez-Manas L. Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol. 2015;3(4):275���85. [PMID: 25466523]
  108. Budnitz DS, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002���12. [PMID: 22111719]
  109. Ben-Ami H, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med. 1999;159(3):281���4. [PMID: 9989540]
  110. McNabney MK, et al. Differences in diabetes management of nursing home patients based on functional and cognitive status. J Am Med Dir Assoc. 2005;6(6):375���82. [PMID: 16286058]
  111. SLYNE C, et al. Assessing the current state of diabetes care in Long-Term facilities using continuous glucose monitoring. Diabetes. 2024;73(Supplement1):145���OR.
  112. Retornaz F, et al. Assessment of glycemic control in nursing home residents with diabetes. J Nutr Health Aging. 2017;21(4):457���63. [PMID: 28346573]
  113. Bouillet B, et al. Frequent and severe hypoglycaemia detected with continuous glucose monitoring in older institutionalised patients with diabetes. Age Ageing. 2021;50(6):2088���93. [PMID: 34324624]
  114. Idrees T, et al. Continuous glucose Monitoring-Guided insulin administration in Long-Term care facilities: A randomized clinical trial. J Am Med Dir Assoc. 2024;25(5):884���8. [PMID: 38460943]
  115. Gomez-Peralta F, et al. A telehealth program using continuous glucose monitoring and a connected insulin pen cap in nursing homes for older adults with insulin-Treated diabetes: the Trescasas study. Diabetes Technol Ther; 2024.
  116. Huang ES, et al. The growing role of technology in the care of older adults with diabetes. Diabetes Care. 2023;46(8):1455���63. [PMID: 37471606]
  117. Stone MP, et al. Retrospective analysis of 3-Month Real-World glucose data after the minimed 670G system commercial launch. Diabetes Technol Ther. 2018;20(10):689���92. [PMID: 30160523]
  118. McAuley SA, et al. Closed-Loop insulin delivery versus Sensor-Augmented pump therapy in older adults with type 1 diabetes (ORACL): A randomized, crossover trial. Diabetes Care. 2022;45(2):381���90. [PMID: 34844995]
  119. Boughton CK, et al. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022;3(3):e135���42. [PMID: 35359882]

MeSH Term

Humans
Long-Term Care
Diabetes Mellitus
Aged
Hypoglycemic Agents
Nursing Homes

Chemicals

Hypoglycemic Agents

Word Cloud

Created with Highcharts 10.0.0diabetescareLTCFsresidentstechnologiesresearchDiabetesmanagementlong-termManagingsignificantsettingsmedicationsinsulinusegapsOlderPURPOSEOFREVIEW:narrativereviewaimsexploreliteratureadvancementswithinfacilitieschronicdiseaseslikeparticularlychallengingduedynamicnatureenvironmentschangesundergonepastdecadeVariousfactorsincludingrisingcostsgovernmentregulationsinfluencequality-of-carereceiveRECENTFINDINGS:Manyextensivelystudiedhigh-risksulfonylureasslidingscalestillpotentiallyincreasingriskmorbiditymortalityamongAdditionallyadoptioncontinuousglucosemonitorsCGMspumpsremainslimitedDespitehighprevalencepersistpotentialgreatlyimproveoutcomesHoweverneededevaluateefficacysafetyFurthermorepressingneedaddressgapstafftrainingClosingessentialdevelopingevidence-basedguidelinesimprovingqualityAdults:CurrentApproachesLong-TermCareFacilitiesLong-termNursinghomesadultsTechnology

Similar Articles

Cited By

No available data.